23 / 28
Gomez de Liaño A. et al, work in progress
Clinical outcome after progressing to frontline and second-line
anti-PD-1/PD-L1 in advanced urothelial cancer
Laterline SST+
Frontline, subsequent treatment (SST)
Laterline no SST
Frontline, no SST
Time from ICI progression (months)
OS, proportion of patients alive